uniQure Q3 2026 net loss narrows to $61.2 million; revenue rises to $5.2 million
uniQure reported third quarter 2026 results with revenue of $5.2 million, up from $3.7 million a year earlier, and a net loss of $61.2 million, or $0.88 per share, versus $80.5 million, or $1.38 per share, in the prior-year quarter. The FDA granted Priority Review to the Biologics License Application for ifezuntirgene inilparvovec in Huntington's disease, with a PDUFA target action date of May 1, 2027, and the company said its $768.4 million in cash and investments is expected to fund operations into 2030.
Key points
- Revenue was $5.2 million for the quarter ended September 30, 2026, up $1.5 million from $3.7 million, driven by higher license revenue.
- Net loss was $61.2 million, or $0.88 per share, compared with $80.5 million, or $1.38 per share, a year earlier.
- The FDA granted Priority Review to the BLA for ifezuntirgene inilparvovec with a PDUFA target action date of May 1, 2027.
- Cash, cash equivalents and investment securities were $768.4 million as of September 30, 2026, which the company expects to fund operations into 2030.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.